Cardiovascular effects of tadalafil

American Journal of Cardiology
92, 37-46
DOI: 10.1016/s0002-9149(03)00074-2

Citation Report

#	Article	IF	Citations
1	Overview of phosphodiesterase 5 inhibition in erectile dysfunction. American Journal of Cardiology, 2003, 92, 9-18.	0.7	172
2	Sexual Activity in Patients With Angina. JAMA - Journal of the American Medical Association, 2003, 290, 3129.	3.8	34
3	A 66-Year-Old Man With Sexual Dysfunction. JAMA - Journal of the American Medical Association, 2004, 291, 2994.	3.8	27
4	Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. Journal of Pharmacy Practice, 2004, 17, 239-250.	0.5	1
5	The efficacy and safety of tadalafil: an update. BJU International, 2004, 93, 1276-1281.	1.3	181
6	Update on Clinical Trials of Tadalafil Demonstrates No Increased Risk of Cardiovascular Adverse Events. Journal of Sexual Medicine, 2004, 1, 161-167.	0.3	46
7	Long-Term Safety and Tolerability of Tadalafil in the Treatment of Erectile Dysfunction. European Urology, 2004, 45, 339-345.	0.9	125
8	Novel phosphodiesterase type 5 inhibitors: Assessing hemodynamic effects and safety parameters. Clinical Cardiology, 2004, 27, 20-25.	0.7	34
9	Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: Comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. Current Urology Reports, 2004, 5, 467-471.	1.0	40
11	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 44, 1488-1496.	1.2	134
12	New phosphodiesterase inhibitors in the treatment of erectile dysfunction. Expert Opinion on Pharmacotherapy, 2004, 5, 2241-2249.	0.9	12
13	New Treatment Options for Erectile Dysfunction in Patients with Diabetes Mellitus. Drugs, 2004, 64, 2667-2688.	4.9	86
14	Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction. Circulation, 2004, 110, 3149-3155.	1.6	167
15	Erectile Dysfunction: Evaluation and New Treatment Options. Psychosomatic Medicine, 2004, 66, 664-671.	1.3	37
16	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. Therapy: Open Access in Clinical Medicine, 2004, 1, 185-196.	0.2	0
18	The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. British Journal of Clinical Pharmacology, 2005, 60, 459-468.	1.1	19
19	Erectile dysfunction in patients with coronary artery disease. International Journal of Impotence Research, 2005, 17, 209-215.	1.0	24
20	A case of erectile dysfunction and risk factors for coronary artery disease. International Journal of Impotence Research, 2005, 17, S7-S11.	1.0	4

#	Article	IF	Citations
21	Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference). American Journal of Cardiology, 2005, 96, 313-321.	0.7	262
22	Hemodynamic and Exercise Effects of Phosphodiesterase 5 Inhibitors. American Journal of Cardiology, 2005, 96, 32-36.	0.7	22
23	Cardiac Safety in Clinical Trials of Phosphodiesterase 5 Inhibitors. American Journal of Cardiology, 2005, 96, 37-41.	0.7	40
24	Pharmacology and Drug Interaction Effects of the Phosphodiesterase 5 Inhibitors: Focus on Î±-Blocker Interactions. American Journal of Cardiology, 2005, 96, 42-46.	0.7	78
25	Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference). American Journal of Cardiology, 2005, 96, 85-93.	0.7	112
26	Comparison of Efficacy, Safety, and Tolerability of Onâ€Demand Tadalafil and Daily Dosed Tadalafil for the Treatment of Erectile Dysfunction. Journal of Sexual Medicine, 2005, 2, 415-427.	0.3	98
27	Nitric oxide and penile erectile function. , 2005, 106, 233-266.		185
28	Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents. Journal of Managed Care Pharmacy, 2005, 11, 151-171.	2.2	36
30	HipertensiÃ³n arterial, medicaciÃ³n antihipertensiva y disfunciÃ³n erÃ©ctil: una perspectiva basada en la evidencia. Revista Internacional De AndrologÃa, 2005, 3, 13-30.	0.1	5
31	The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction. Journal of Clinical Pharmacology, 2005, 45, 987-1003.	1.0	153
32	Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opinion on Pharmacotherapy, 2005, 6, 75-84.	0.9	54
33	Phosphodiesterase 5 Inhibitors for Erectile Dysfunction. Annals of Pharmacotherapy, 2005, 39, 1286-1295.	0.9	69
34	A Comparative Review of the Options for Treatment of Erectile Dysfunction. Drugs, 2005, 65, 1621-1650.	4.9	155
35	CHAPTER 1: THE MANAGEMENT OF ERECTILE DYSFUNCTION: AN AUA UPDATE. Journal of Urology, 2005, 174, 230-239.	0.2	295
36	Safety and Tolerability of Oral Erectile Dysfunction Treatments in the Elderly. Drugs and Aging, 2005, 22, 323-338.	1.3	7
37	Erectile Dysfunction in the Patients with Cardiovascular Disease. Korean Journal of Urology, 2006, 47, 279.	0.2	3
39	Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. Coronary Artery Disease, 2006, 17, 493-499.	0.3	8
40	Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. British Journal of Clinical Pharmacology, 2006, 62, 280-287.	1.1	18

#	Article	IF	Citations
41	Preference studies are of value to the field of sexual medicine: Con. Current Sexual Health Reports, 2006, 3, 9-12.	0.4	0
42	Sexual activity after myocardial infarction: When to resume the use of erectogenic drugs. Current Sexual Health Reports, 2006, 3, 30-34.	0.4	3
43	Erectile dysfunction and cardiac disease: Recommendations of the second princeton conference. Current Urology Reports, 2006, 7, 490-496.	1.0	25
44	Cardiovascular Effects of Phosphodiesterase 5 Inhibitors. Current Pharmaceutical Design, 2006, 12, 3485-3494.	0.9	50
45	Side effects of using nitrates to treat angina. Expert Opinion on Drug Safety, 2006, 5, 667-674.	1.0	77
46	Sex, the Heart, and Heart Failure. Seminars in Cardiothoracic and Vascular Anesthesia, 2006, 10, 256-258.	0.4	6
47	Sexual Dysfunction and Chronic Illness: The Role of Flexibility in Coping. Journal of Sex and Marital Therapy, 2006, 32, 235-253.	1.0	41
48	Erectile dysfunction and coronary atherothrombosis in diabetic patients: pathophysiology, clinical features and treatment. Expert Review of Cardiovascular Therapy, 2006, 4, 173-180.	0.6	16
49	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. International Journal of Impotence Research, 2007, 19, 139-148.	1.0	49
50	Erectile dysfunction and hypertension. International Journal of Impotence Research, 2007, 19, 296-302.	1.0	78
51	Metabolic Risk Factors, Endothelial Dysfunction, and Erectile Dysfunction in Men With Diabetes. American Journal of the Medical Sciences, 2007, 334, 466-480.	0.4	15
52	Type 5 Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction and Cardiovascular Disease. Cardiology in Review, 2007, 15, 76-86.	0.6	65
53	The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. International Journal of Impotence Research, 2007, 19, 55-61.	1.0	70
54	Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: A meta-analysis of randomized trials. American Heart Journal, 2007, 153, 343-353.	1.2	135
55	Side effects of using nitrates to treat heart failure and the acute coronary syndromes, unstable angina and acute myocardial infarction. Expert Opinion on Drug Safety, 2007, 6, 385-396.	1.0	21
56	Effect of tadalafil on anaerobic performance indices in healthy athletes. British Journal of Sports Medicine, 2007, 42, 130-133.	3.1	18
57	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. International Journal of Impotence Research, 2007, 19, 281-295.	1.0	35
58	Diagnosis and management of erectile dysfunction in the primary care setting. International Journal of Clinical Practice, 2007, 61, 1198-1208.	0.8	19

#	Article	IF	Citations
59	Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. International Journal of Clinical Practice, 2007, 61, 1547-1554.	0.8	24
60	Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications. European Urology, 2007, 52, 990-1005.	0.9	49
62	Phosphodiesterase 5 inhibition in essential hypertension. Current Hypertension Reports, 2008, 10, 52-57.	1.5	32
63	Erectile Dysfunction and Dyslipidemia: Relevance and Role of Phosphodiesterase Type-5 Inhibitors and Statins. Journal of Sexual Medicine, 2008, 5, 1066-1078.	0.3	51
64	Does Sildenafil Cause Myocardial Infarction or Sudden Cardiac Death?. American Journal of Cardiovascular Drugs, 2008, 8, 1-7.	1.0	23
65	The cardiovascular safety of tadalafil. Expert Opinion on Drug Safety, 2008, 7, 43-52.	1.0	11
66	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. European Respiratory Journal, 2008, 32, 198-209.	3.1	129
67	Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. European Heart Journal, 2008, 29, 3002-3010.	1.0	229
68	Response to treatment with tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. International Journal of Impotence Research, 2008, 20, 554-560.	1.0	6
69	Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease. International Journal of Impotence Research, 2008, 20, 168-172.	1.0	2
70	Sexual dysfunction: the â€˜prima ballerinaâ€™ of hypertension-related quality-of-life complications. Journal of Hypertension, 2008, 26, 2074-2084.	0.3	113
71	Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management, 2008, Volume 4, 1315-1329.	0.9	86
72	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacologica Sinica, 2009, 30, 1-24.	2.8	49
73	Factors Influencing the Benefit of Adjunctive Devices during Percutaneous Coronary Intervention in STâ€Segment Elevation Myocardial Infarction: Metaâ€Analysis and Metaâ€Regression. Journal of Interventional Cardiology, 2009, 22, 49-60.	0.5	6
74	Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. American Journal of Lifestyle Medicine, 2009, 3, 201-211.	0.8	1
75	Phosphodiesterase 5 inhibitors: are they cardioprotective?. Cardiovascular Research, 2009, 83, 204-212.	1.8	33
76	Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension. Circulation, 2010, 122, 88-95.	1.6	102
77	The phosphodiesterases type 5 inhibitor tadalafil reduces the activation of the hypothalamus-pituitary-adrenal axis in men during cycle ergometric exercise. American Journal of Physiology - Endocrinology and Metabolism, 2012, 302, E972-E978.	1.8	17

#	Article	IF	Citations
78	Cardiac Uses of Phosphodiesterase-5 Inhibitors. Journal of the American College of Cardiology, 2012, 59, 9-15.	1.2	83
79	Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability. Journal of Sexual Medicine, 2012, 9, 2122-2129.	0.3	65
80	Assessment of the Effect of Mirodenafil on the Hemodynamics of Healthy Male Korean Volunteers Administered Tamsulosin: A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study. Clinical Therapeutics, 2012, 34, 1929-1939.	1.1	7
81	Andrological aspects of physical exercise and sport medicine. Endocrine, 2012, 42, 278-284.	1.1	59
82	Tadalafil. Drugs and Aging, 2012, 29, 771-781.	1.3	9
83	Antihypertensive Treatment and Sexual Dysfunction. Current Hypertension Reports, 2012, 14, 285-292.	1.5	85
84	10â€Year Analysis of Adverse Event Reports to the Food and Drug Administration for Phosphodiesterase Typeâ€5 Inhibitors. Journal of Sexual Medicine, 2012, 9, 265-270.	0.3	38
85	Sexual Activity and Ischemic Heart Disease. Current Cardiology Reports, 2014, 16, 445.	1.3	21
86	Cardioprotective role of tadalafil against cisplatin-induced cardiovascular damage in rats. European Journal of Pharmacology, 2015, 765, 574-581.	1.7	12
88	Effects of mirodenafil on the hemodynamics in hypertensive patients taking amlodipine. Translational and Clinical Pharmacology, 2016, 24, 90.	0.3	0
89	Technological Device for Manufacturing Transdermal Films: Possible Applications to the Individualized Treatment for Erectile Dysfunction. AAPS PharmSciTech, 2017, 18, 2824-2831.	1.5	1
90	Sildenafil (ViagraTM): Synthesis Step by Step and its Pharmaceutical Importance in Diabetic Patients with Erectile Dysfunction. , 2018, 08, .		1
91	Exercise, training, and the hypothalamicâ€"pituitaryâ€"gonadal axis in men. Current Opinion in Endocrine and Metabolic Research, 2019, 9, 86-89.	0.6	0
92	Targeting Nitric Oxide for Bone Disease. , 2020, , 666-696.		2
93	Ruthenium Catalyzed Tandem Pictetâ€"Spengler Reaction. Organic Letters, 2020, 22, 4979-4984.	2.4	19
94	Emergency Drugs for the Oral and Maxillofacial Surgeon Office. Oral and Maxillofacial Surgery Clinics of North America, 2021, 34, 1-7.	0.4	0
95	Sex and Chronic Physical Illness. , 2017, , 479-506.		2
97	RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity. Journal of Clinical Investigation, 2019, 129, 2318-2332.	3.9	32

#	Article	IF	Citations
98	Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. Clinical Interventions in Aging, 2006, 1, 439-449.	1.3	18
99	Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. , 2004, , 159-181.		0
100	Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. , 2004, , 129-142.		0
101	An Update on Pharmacological Treatment of Erectile Dysfunction. European Endocrinology, 2006, , 81.	0.8	0
102	Drug Interaction Study of Vardenafil 20mg and Doxazosin 4mg or Tamsulosin 0.2mg in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction to Evaluate Changes in Blood Pressure. Korean Journal of Urology, 2006, 47, 1001.	0.2	0
103	Erectile Dysfunction and Cardiovascular Disease. , 2007, , 2791-2801.		0
105	Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. , 2011, , 1477-1485.		1
106	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. Therapy: Open Access in Clinical Medicine, 2004, 1, 185-196.	0.2	0
107	Pharmacotherapy of sexual dysfunctions : current status. Indian Journal of Psychiatry, 2004, 46, 213-20.	0.4	6
109	Application of Modern Analytical Techniques for quantification of Tadalafil in Pharmaceutical and Biological Matrices: Future Prospectus.. Current Pharmaceutical Analysis, 2022, 19, .	0.3	0
110	Recent Progress for the Synthesis of Î²-Carboline Derivatives â€“ an Update. Polycyclic Aromatic Compounds, 0, , 1-26.	1.4	0